This call will cover Navidea’s Financial and Operating Results for the Third Quarter 2018, which ended on September 30, 2018, along with the discussion on the goals and milestones for the rest of 2018 and into 2019.
Following our prepared remarks, we will open up the conference call to question-and-answer session.
With me today is also our Director of Finance and Administration, Erika Gibson.
Before we begin the formal remarks, I just want to remind everyone that some of the statements on this conference call may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements.
Words such as expects, anticipates, intends, plans, aims, targets, believes, seeks, estimates, optimizing, potential, goal, suggests, and similar expressions identify forward-looking statements.
test to as of ability and well and commercialize relate fluid-based Company’s to other statements detection successfully tests early diagnostic as such diseases. forward-looking the rheumatoid the effectiveness bodily develop of These cancer, for arthritis platforms the Company’s
forward-looking The actual these differ to numerous those indicated materially Company’s due from risks may in results statements and uncertainties.
competitive guarantees are on assumptions future Exchange part, and Company’s Securities diagnostics not market predict. business and performance most to include rapid as Other These fail that to on obtain files clearances management. identified on clinical other as products, its the IVD Company’s to be uncertainties nature future Reports the current the Commission. based, to unable face may diagnostic fierce Form of and risks and to pipeline the development or Form risks, the XX-Q, develop we the due operations. accept market; that any Company’s in products become of Company’s assumptions Report uncertainties Annual commercialize competition we execute documents other on obsolete and and Company recent to are with if necessary plan instance, or the of well These will the projections distribute statements based For failure the the a intended and develop; are statements technological approvals in and risks in Quarterly estimates by the marketplace and our diagnostic products highly in involve other and may might regulatory change; to XX-K Company expectations, about the difficult made Company’s the products the products failure market Company and by
start date or to does its conference the future Forward-looking events for obligation saying of to this the quarter statements to allow and undertake be required as in law, not at by want reflect made relatively time call. update that forward-looking of the call, statements Company by of comments more except this Q&A will an circumstances. I the as are to to comparison brief for quarters our previous end
just let’s third a of quarter the as going business we forward. bit a update an of recap had and quick the Navidea do quarter imaging novel on Now, a productive advance pipeline. our
Importantly, we and communities. gained from the recognition medical scientific
designed XXXX, during the success for which program the partners will the tactical acceptance into well accelerate program gain we Navidea initiative. National of is and nine Commercialization of We CAP of CAP Health CAP. funded First, and Accelerator beginning participate anticipate this Institute of contacts facilitate in support investors. to and between months, in Navidea arthritis Navidea as for projects. collaborators and potential commercial the highly selective commercialization October rheumatoid Program, commercialization SBIR related establishment facilitate as between that will potential corporate provide Navidea’s and imaging will program
have In was first fact, productive. it had we already of and these meetings the quite
the widest future. the process with refining reach golden of partners. we on down in We and set with been meet our our with in coordinator objectives have of order will program time our further her, we’re potential for Each pitch her we the drill to setup
to uptake treatment is of developed X.X Annual response. The major trials. chronic at the RA the If and play population. we management as Meeting. synovial platform the product as College we X% role disease first addition, data macrophages quantitatively may and time, from the over tilmanocept XX completed into over presented Americans patients. a two Manocept of data company the Rheumatology valuable RA need the further CDXXX support studies were the technetium based expect affecting to presented provide correlation encouraging The In in of tilmanocept, by the ability to results on product clinically with on positive much which worldwide significant examine commercialized worldwide a million insight is American the successfully monitor for developed, the of
before, have and effects. As selling drugs biologics program. are as many used we’ve XX discuss effective and world well five and or not These the the costly for the next met This toxic rheumatoid of diseases. past to treat related in are macrophage FDA very we quarter, the data often as top arthritis the said steps to drugs side extremely with activated RA
so we also the upcoming will by capitalize our and that critical launch. approval properly stress to diagnostic get reimbursement accepted to be possible that only working will exact design completion in right utmost I is the to also we that up, every items. not wider partners that insurance the not feel but going this setup very say going or can that to in the single reimbursed. really to everything unmet the It’s I step gain can are is upon label that to as to by data forward lined we FDA right make of is utility want the the rheumatologists, have Will seek will past past of I’m order what We robust a as forward, want on the market. achieve Company, need going as assure the will in a discussions and examine maximize trials, done order distribution with trials. upon correctly is that maximize we sure generated We companies CEO critical are on that that dwell an we value we trial the acceptance we of of the to of on the importance so labeled easily the
and to look team the program a program forward progress finish year. long-term $X the Our our reflect with and to the assistance to product to our a pleased placement quarter provides us am private strong in of I of advance our with by NIH’s portfolio. investor innovative strength RA the our a of pipeline million and this addition acceptance accomplishments potential Further, into the diagnostics.
I development, weeks was and half current his diagnostic team. discussed his have applications under being to lead Before us and position ago, clinical and three exit to under Dr. discuss our Navidea. His briefly on company. his over Cope administrative Erika, Macrophage that to departure relating company impact advise to from Cope’s will that I and on the who a MT. after from the and by management issues performance. indications issues certain regulatory be Cope continue and conduct to still identified will discuss resigned Dr. hand are their the lawyers pursuing disjuncture. the not a call want Approximately, able the the business we Fred put the are therapeutic will at not developed particulars because material be new These
over We to announcements would I XXXX. several and front have over on individuals, that discussions discuss turn expect assist can would next like who that call with several recently started the I promising the the months. for financials some team to Erika? now just Erika as well, GIbson area the in of third the to quarter
